

Manufacturer	NDC 11	Drug Name	Commercial Launch Date
Boehringer Ingelheim Pharmaceuticals, Inc.	00597062020	Spevigo	4/15/2024

Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	The estimated volume of patients who may be prescribed the drug	Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval
<p>Specific Marketing and Pricing Plans for Spevigo are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, consideration for access to patients and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 22.5% of its net sales into research and development, including clinical trials.</p>	<p>7,500</p>	<p>Y</p>

Date and price of acquisition if the drug was not developed by the manufacturer

N/A